Skip to main content

Table 1 Baseline characteristics of the study cohort

From: Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study

  

MW ± SD n (%)

Randomisation

Group A

7 (23.3)

Group B

9 (30.0)

Group C

1 (3.3)

Group D

13 (43.3)

Demography

Age (years)

54 ± 11

Height (m)

1.65 ± 0.07

BMI (kg/m2)

26.0 ± 4.6

Diagnosis

Adjuvant

26 (86.7)

Metastatic or local advanced

4 (13.3)

Tumour entity

Breast Cancer

22 (73,33)

Endometrial Cancer

2 (6,7)

Ovarian Cancer

2 (6.7)

Cervical Cancer

4 (13,3)

T-categories

T1

10 (33.3)

T2

14 (46.7)

T3

3 (10.0)

T4

3 (10.0)

Nodal status

N0

20 (66.7)

N1

8 (26.7)

N2

1 (3.3)

N3

1 (3.3)

Metastasis

M0

27 (90.0)

M1

3 (10.0)

Chemotherapy regimens

Paclitaxel/Carboplatin

7 (23.3)

Epirubicin/Cyclophosphamid

22 (73.3)

Docetaxel/Cyclophosphamid

1 (3.3)

Treatment

Adjuvant chemotherapy

6 (20)

Neoadjuvant chemotherapy

22 (73.3)

Palliative chemotherapy

3 (10.0)

Nutritional status (NRS 2002)

1

21 (70.0)

2

8 (26.7)

3

1 (3.3)

Energy requirement

Basal metabolic rate (kcal)

1391 ± 125

Physical Activity Level

1.39 ± 0.06

Active metabolic rate (kcal)

1933 ± 178

25% of the active metabolic rate (kcal)

484 ± 44